87326-31-6

Upstream product

• 100-39-0 benzyl bromide 
• 1056479-53-8 allyl-4,6-O-benzylidene-2,3-di-O-hydroxy-D-mannopyranoside 
• 100-44-7 benzyl chloride 
• 530-26-7 D-Mannose 
• 182212-07-3 α,β-O-allyl-D-mannopyranoside 
• 618-31-5 benzylidene dibromide 
• 65987-12-4 1-O-allyl-4,6-O-benzylidene-α-D-glucopyranoside 
• 7464-56-4 1-O-allyl-α-D-glucopyranoside 
• 492-62-6 alpha-D-glucopyranose 
• 100-52-7 benzaldehyde 
• 4163-65-9 per-O-acetyl-α-D-mannopyranose 
• 214490-84-3 Allyl 2,3,4,6-Tetra-O-acetyl-D-mannopyranoside 
• 119111-33-0 (3aS,5aR,8R,9aR,9bS)-4-Allyloxy-2,8-diphenyl-hexahydro-[1,3]dioxolo[4',5':4,5]pyrano[3,2-d][1,3]dioxine 
• 2280-44-6 D-Glucose 

Downstream Products

• 912651-00-4 2,3,6-tri-O-benzyl-D-mannono-1,5-lactone 
• 912650-53-4 3,4,5,7-tetra-O-benzyl-1-deoxy-α-D-gluco-hept-2-ulosyl-(2->4)-2,3,6-tri-O-benzyl-D-mannono-1,5-lactone 
• 912650-56-7 3,4,5,7-tetra-O-benzyl-1-deoxy-α-D-galacto-hept-2-ulosyl-(2->4)-2,3,6-tri-O-benzyl-D-mannono-1,5-lactone 
• 912650-59-0 3,4,5,7-tetra-O-benzyl-1-deoxy-α-D-manno-hept-2-ulosyl-(2->4)-2,3,6-tri-O-benzyl-D-mannono-1,5-lactone 
• 119237-94-4 <2R-(2α,4aβ,5α,6β,7β,7aβ)>-Hexahydro-5-methyl-2-phenyl-6,7-bis(phenylmethoxy)cyclopenta-1,3-dioxin 
• 119237-95-5 <2R-(2α,4aβ,5β,6β,7β,7aβ)>-Hexahydro-5-methyl-2-phenyl-6,7-bis(phenylmethoxy)cyclopenta-1,3-dioxin 
• 119237-93-3 (R)-1,2-Dideoxy-3,4-bis-O-(phenylmethyl)-5,7-O-(phenylmethylene)-D-manno-hept-1-enitol 
• 119111-10-3 Imidazole-1-carbothioic acid O-[(2R,4R,5R)-4-((1R,2R)-1,2-bis-benzyloxy-but-3-enyl)-2-phenyl-[1,3]dioxan-5-yl] ester 
• 78184-40-4 1-O-allyl-2,3,4-tri-O-benzyl-α-D-glucopyranoside 
• 153097-69-9 allyl 2,3,6 tri-O-benzyl-α-D-glucopyranoside 
• 87907-01-5 methyl (2,3-di-O-benzyl-4-O-chloroacetyl-α-D-glucopyranosyl bromide)uronate 
• 93338-32-0 methyl 2,3-di-O-benzyl-4-O-chloroacetyl-D-glucopyranuronate 
• 87907-02-6 O-(methyl 2,3-di-O-benzyl-4-O-(chloroacetyl)-β-D-glucopyranosyluronate)-(1->4)-3-O-acetyl-1,6-anhydro-2-azido-2-deoxy-β-D-glucopyranose 
• 157399-19-4 (1R,22S,24R,25S,26R)-25,26-Bis-benzyloxy-24-benzyloxymethyl-2,5,8,15,18,21,23-heptaoxa-tricyclo[20.2.2.0^9,14]hexacosa-9,11,13-triene 

Relevant academic research and scientific papers

The compound or its salt, and radiation sensitizer

In combination with the novel pharmaceutical compound [a] tumors to radiation. (I) represented by the following formula [a] compound or a salt thereof. In the formula (I), R1 C is1 - C26 The aliphatic hydrocarbon group. Fi

Distribution and metabolism of 14C-sulfoquinovosylacylpropanediol (14C-SQAP) after a single intravenous administration in tumor-bearing mice

Sulfoquinovosylacylpropanediol (SQAP) is a novel potent radiosensitizer that inhibits angiogenesis in vivo and results in increased oxigenation and reduced tumor volume. We investigated the distribution, metabolism, and excretion of SQAP in male KSN-nude mice transplanted with a human pulmonary carcinoma, Lu65.For the metabolism analysis, a 2?mg (2.98?MBq)/kg of [glucose-U-14C]-SQAP (CP-3839) was intravenously injected. The injected SQAP was decomposed into a stearic acid and a sulfoquinovosylpropanediol (SQP) in the body.The degradation was relatively slow in the carcinoma tissue.1,3-propanediol[1-14C]-SQAP (CP-3635) was administered through intravenous injection of a 1?mg (3.48?MBq)/kg dose followed by whole body autoradiography of the mice.The autoradiography analysis demonstrated that SQAP rapidly distributed throughout the whole body and then quickly decreased within 4 hours except the tumor and excretion organs such as liver, kidney.Retention of SQAP was longer in tumor parts than in other tissues, as indicated by higher levels of radioactivity at 4 hours. The radioactivity around the tumor had also completely disappeared within 72 hours.

Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same

Sulfoquinovosylacyl propanediol compounds represented by formula (I): wherein R1 is an acyl residue of a fatty acid, Y is a number of 1, 2 or 3, and M represents a cation having a positive charge equal to Y and pharmaceutically acceptable salts

Synthesis of 1-deoxyhept-2-ulosyl-glycono-1,5-lactone utilizing α-selective O-glycosidation of 2,6-anhydro-1-deoxy-d-hept-1-enitols

A series of 1-deoxy-heptulo-2-pyranosyl-glycono-1,5-lactones were synthesized utilizing completely α-selective O-glycosidation of heptenitols. Anomeric configuration of the products was confirmed by 3JC,H coupling measurement and X-ray crystal structural analysis. The benzyl-protected ketosyl saccharides were partly unstable, and glycosidic linkage was prone to cleave under the usual debenzylation conditions. To prevent this, we surveyed various additives for the Pd-catalyzed hydrogenation reaction and found that basic alumina was the most effective.

Chiral crown ethers incorporating D-glucose

A novel class of crown ether derivatives incorporating D-glucose and poly(ethylene glycol) units has been synthesized from allyl α-D-glucopyranoside by a simple and efficient strategy.The complexing properties of these compounds with alkali metal cations and ammonium ion have been evaluated by Cram's picrate method.Catalytic activity of macrocycle 2 in asymmetric Michael addition reaction was also studied.The average cavity size of these macrocycles was determined by the application of the MMX programme.

Synthesis of Novel Chiral Macrocycles: Crown Ethers Derived from D-Glucose

Two new macrocycles (1 and 2) incorporating a crown ether and a glucose unit have been synthesized efficiently in six steps from α-allyl glucopyranoside.Preliminary complexation studies with alkali metal and ammonium ions are described.

Stereochemical Control in Hex-5-enyl Radical Cyclizations: From Carbohydrates to Carbocycles. 3

The hex-5-enyl radical cyclization reaction was applied to prepare highly oxygenated cyclopentanoids from aldopyranose sugars.The Wittig reaction of the sugars readily provides hex-5-en-1-ols which were converted to hex-5-enyl radicals via one of the vari